

## Correction to

NOSTRA Investigators

DOI:

[10.1186/s13063-020-4107-8](https://doi.org/10.1186/s13063-020-4107-8)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

NOSTRA Investigators 2020, 'Correction to: Ronopterin (VAS203) in patients with moderate and severe traumatic brain injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study', *Trials*, vol. 21, no. 1, 172. <https://doi.org/10.1186/s13063-020-4107-8>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

CORRECTION

Open Access



# Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study

Frank Tegtmeier<sup>1</sup>, Reinhard Schinzel<sup>1\*</sup>, Ronny Beer<sup>2</sup>, Diederik Bulters<sup>3</sup>, Jean-Yves LeFrant<sup>4</sup>, Joan Sahuquillo<sup>5</sup>, Andreas Unterberg<sup>6</sup>, Peter Andrews<sup>7</sup>, Antonio Belli<sup>8</sup>, Javier Ibanez<sup>9</sup>, Alfonso Lagares<sup>10</sup>, Michael Mokry<sup>11</sup>, Harald Willschke<sup>12</sup>, Charlotte Flüh<sup>13</sup>, Erich Schmutzhard<sup>2</sup> and on behalf of the NOSTRA Investigators

**Correction to: *Trials* (2020) 21:80**

**<https://doi.org/10.1186/s13063-019-3965-4>**

After publication of our article [1] the authors have notified us that one of the names has been incorrectly spelled.

- Original name spelling:  
Charlotte Flühe
- Correct name spelling:  
Charlotte Flüh

The original article has been corrected.

Published online: 12 February 2020

## Reference

1. Tegtmeier, et al. Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study. *Trials*. 2020;21:80. <https://doi.org/10.1186/s13063-019-3965-4>.

## Author details

<sup>1</sup>vasopharm GmbH, Würzburg, Germany. <sup>2</sup>Medizinische Universität Innsbruck, Innsbruck, Austria. <sup>3</sup>Wessex Neurological Centre University Hospital, Southampton, UK. <sup>4</sup>Hopital Universitaire Caremeau, Nimes, France. <sup>5</sup>Vall d'Hebron University Hospital, Barcelona, Spain. <sup>6</sup>Universitätsklinikum Heidelberg, Heidelberg, Germany. <sup>7</sup>Western General Hospital Lothian University, Edinburgh, UK. <sup>8</sup>Queen Elizabeth Hospital, Birmingham, UK. <sup>9</sup>Espases University Hospital, Palma de Mallorca, Spain. <sup>10</sup>Hospital Universitario 12 de Octubre, Madrid, Spain. <sup>11</sup>LKH – Universitätsklinikum Graz, Graz, Austria. <sup>12</sup>Medizinische Universität Wien, Wien, Austria. <sup>13</sup>Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

The original article can be found online at <https://doi.org/10.1186/s13063-019-3965-4>

\* Correspondence: [schinzel@vasopharm.de](mailto:schinzel@vasopharm.de)

<sup>1</sup>vasopharm GmbH, Würzburg, Germany

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.